Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK^® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis

AlloNK is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved natural killer cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity.